

# ACIP Hepatitis Work Group: Introduction

Mark Sawyer, MD – Chair

October 25, 2012

National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention

Division of Viral Hepatitis



# ACIP Hepatitis Work Group

- ❑ Mark Sawyer, ACIP, Chair
- ❑ Douglas Campos-Outcalt, ACIP
- ❑ Jonathan Temte, ACIP
- ❑ Alexis Elward, HICPAC Liaison
- ❑ Stephen Feinstone, FDA
- ❑ Kathleen Harriman, CDPH
- ❑ Samuel Katz, Former ACIP Chair
- ❑ Harry Keyserling, SHEA Liaison
- ❑ Thomas Koinis, AAHP
- ❑ Myron Levin, Former ACIP Chair
- ❑ Marian Major, FDA
- ❑ Brian McMahon, ANTHC
- ❑ Amy Middleman, SAHM Liaison
- ❑ David Nace, AMDA
- ❑ Georges Peter, Brown U
- ❑ Brenna Simons, ANTHC
- ❑ James Turner, ACHA Liaison
- ❑ David Weber, SHEA
- ❑ Geoff Beckett, CDC/DVH
- ❑ Kathy Byrd, CDC/DVH
- ❑ Scott Holmberg, CDC/DVH
- ❑ Erin Kennedy, CDC/ISD
- ❑ David Kuhar, CDC/DHQP
- ❑ Trudy Murphy, CDC/DVH
- ❑ Marie de Perio, NIOSH
- ❑ Sarah Schillie, CDC/DVH
- ❑ Philip Spradling, CDC/DVH
- ❑ Eyasu Teshale, CDC/DVH
- ❑ Cindy Weinbaum, CDC/DHQP
- ❑ Fujie Xu, CDC/DVH

# Term of Reference

- ❑ Ensure hepatitis B protection for healthcare personnel (HCP), including trainees, who have written documentation of Hepatitis B (HepB) vaccination in the past without post-vaccination serologic testing
- ❑ ACIP requested Hepatitis Work Group deliberation

# Background

- ❑ **1982: ACIP recommended HepB vaccination for HCP<sup>1</sup>**
  - In past, most HCP, including trainees, unvaccinated until matriculation or hire
- ❑ **1997: ACIP recommended post-vaccination serologic testing 1-2 months after vaccination for HCP at ongoing risk for percutaneous injury<sup>2</sup>**
  - Determines need for revaccination
  - Guides post-exposure management

<sup>1</sup>MMWR 1982, <sup>2</sup>MMWR 1997

# What is Different Now?

- ❑ Increasing proportion of HCP entering training and workforce have received HepB vaccination as infants or in the distant past
  - Birth dose prevents chronic infection (when risk is greatest)
- ❑ Post-vaccination serologic testing (antibody to hepatitis B surface antigen, anti-HBs) not recommended after routine infant HepB vaccination
- ❑ Anti-HBs after vaccination wanes over time, although protection believed to persist

# Changing Context for Occupationally-Acquired Hepatitis B

- Healthcare schools and institutions seeking guidance:
  - How to identify and ensure protection for initial  $\geq 3$  dose non-responders

# Topics Covered by Work Group

1. Changing epidemiology of hepatitis B
2. HCP risk of blood and body fluid (BBF) exposure<sup>1</sup>
3. HCP rates of reporting BBF exposures<sup>1</sup>
4. Probability of hepatitis B surface antigen (HBsAg)-positive source patient<sup>1</sup>
5. Efficacy of hepatitis B immune globulin (HBIG) for post-exposure prophylaxis

<sup>1</sup>Predominantly since 2002

# Topics Covered by Work Group, cont.

6. HCP HepB vaccine coverage
7. Evidence of serologic and clinical protection after vaccination with HepB primary series
8. Evidence of serologic protection after “challenge” dose of HepB vaccine
9. Long-term HepB vaccine protection
10. Acute hepatitis B among HCP
11. Current practices (California) survey



# Hepatitis Work Group Activities

- ❑ 19 Work Group teleconferences
- ❑ Presentation at HICPAC
  - June 2012
- ❑ Presentations at two ACIP meetings
  - February 2012
  - June 2012

# Considerations for Guidance<sup>1</sup>

- ❑ Pre-exposure evaluation for protection
- ❑ Post-exposure management with evaluation for continuing protection

Presented  
to ACIP,  
June 2012

<sup>1</sup>Applies to both trainees and non-trainees

# Today's Presentations

- ❑ **Hepatitis B among HCP**
  - Continuing risk for hepatitis B virus exposure
  - Hepatitis B vaccine coverage
  - National surveillance
- ❑ **Updates to cost-effectiveness analyses**
- ❑ **Long-term protection**
- ❑ **Current practices**
- ❑ **Proposed guidance**